PASW Ping An Biomedical Co., Ltd.
Fundamentals / CIK 0001897532 / CNYPing An Biomedical Co., Ltd. reported ¥34.15M in revenue and a net loss of ¥12.83M for the fiscal year ended September 30, 2025 (down 61.0% year over year), with a 2.8% gross margin and a -43.1% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open PASW in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025¥34.15M -61.0% YoY
-
Operating Income FY 2025-¥14.70M -43.1% margin
-
Net Income FY 2025-¥12.83M -37.6% net margin
-
Diluted EPS FY 2025-¥0.69 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2025¥1.17M Total debt: ¥10.47M
Annual revenue and net income
3 fiscal years (2023 to 2025), reported in CNY.
Financial statements and ratios
Reported in CNY. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in CNY · Newest filing period first.
| Income Statement | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|
| Revenue | ¥34.15M | ¥87.62M | ¥82.56M |
| Cost of Revenue | ¥33.20M | ¥82.21M | ¥78.32M |
| Gross Profit | ¥950K | ¥5.42M | ¥4.24M |
| Selling, General & Admin | ¥6.31M | ¥5.30M | ¥3.60M |
| Total Operating Expenses | ¥15.65M | ¥5.42M | ¥3.63M |
| Operating Income | -¥14.70M | -¥2.0K | ¥612K |
| EBITDA | -¥14.70M | ¥8.2K | ¥645K |
| Interest Income | ¥326K | ¥2.0K | ¥156K |
| Interest Expense | ¥307K | ¥705K | ¥1.74M |
| Income Before Tax | -¥14.68M | -¥683K | ¥42K |
| Income Tax Expense | ¥1.86M | -¥601K | -¥1.04M |
| Net Income | -¥12.83M | -¥1.28M | -¥994K |
| Basic EPS | -¥0.69 | -¥0.07 | -¥0.06 |
| Diluted EPS | -¥0.69 | -¥0.07 | -¥0.06 |
| Basic Shares Outstanding | 18.5M | 18.0M | 18.0M |
| Diluted Shares Outstanding | 18.5M | 18.0M | 18.0M |
Income Statement (Quarterly) · Reported in CNY · Newest filing period first.
Balance Sheet (Annual) · Reported in CNY · Newest filing period first.
| Balance Sheet | Sep 30 | Sep 30 |
|---|---|---|
| Cash & Cash Equivalents | ¥1.17M | ¥131K |
| Cash & Short-Term Investments | ¥1.17M | ¥131K |
| Accounts Receivable, Net | ¥16.93M | ¥40.44M |
| Inventory | ¥442K | ¥127K |
| Total Current Assets | ¥63.70M | ¥53.31M |
| Property, Plant & Equipment, Net | -- | ¥5.6K |
| Total Non-Current Assets | ¥4.72M | ¥3.54M |
| Total Assets | ¥68.41M | ¥56.85M |
| Accounts Payable | ¥9.41M | ¥15.06M |
| Short-Term Debt | ¥10.00M | ¥10.00M |
| Deferred Revenue (Current) | ¥70K | ¥1.67M |
| Total Current Liabilities | ¥23.08M | ¥63.58M |
| Total Non-Current Liabilities | ¥96K | ¥461K |
| Total Liabilities | ¥23.17M | ¥64.04M |
| Total Debt (incl. Leases) | ¥10.47M | ¥10.81M |
| Common Stock | ¥8.4K | ¥7.3K |
| Retained Earnings | -¥21.05M | -¥8.22M |
| Accumulated Other Comp. Income | -¥1.61M | -¥657K |
| Total Stockholders' Equity | ¥45.24M | -¥7.19M |
| Total Equity | ¥45.24M | -¥7.19M |
Balance Sheet (Quarterly) · Reported in CNY · Newest filing period first.
| Balance Sheet | 2025-09-30 | 2024-09-30 |
|---|---|---|
| Cash & Cash Equivalents | ¥1.17M | ¥131K |
| Cash & Short-Term Investments | ¥1.17M | ¥131K |
| Accounts Receivable, Net | ¥16.93M | ¥40.44M |
| Inventory | ¥442K | ¥127K |
| Total Current Assets | ¥63.70M | ¥53.31M |
| Property, Plant & Equipment, Net | -- | ¥5.6K |
| Total Non-Current Assets | ¥4.72M | ¥3.54M |
| Total Assets | ¥68.41M | ¥56.85M |
| Accounts Payable | ¥9.41M | ¥15.06M |
| Short-Term Debt | ¥10.00M | ¥10.00M |
| Deferred Revenue (Current) | ¥70K | ¥1.67M |
| Total Current Liabilities | ¥23.08M | ¥63.58M |
| Total Non-Current Liabilities | ¥96K | ¥461K |
| Total Liabilities | ¥23.17M | ¥64.04M |
| Total Debt (incl. Leases) | ¥10.47M | ¥10.81M |
| Common Stock | ¥8.4K | ¥7.3K |
| Retained Earnings | -¥21.05M | -¥8.22M |
| Accumulated Other Comp. Income | -¥1.61M | -¥657K |
| Total Stockholders' Equity | ¥45.24M | -¥7.19M |
| Total Equity | ¥45.24M | -¥7.19M |
Cash Flow Statement (Annual) · Reported in CNY · Newest filing period first.
| Cash Flow Statement | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|
| Net Income | -¥12.83M | -¥1.28M | -¥994K |
| Depreciation & Amortization | ¥5.6K | ¥10K | ¥33K |
| Change in Receivables | ¥14.17M | ¥6.53M | ¥9.88M |
| Change in Inventory | -¥308K | ¥3.06M | ¥1.44M |
| Change in Payables | -¥5.64M | ¥5.78M | -¥8.76M |
| Operating Cash Flow | -¥6.43M | ¥14.63M | -¥6.08M |
| Investing Cash Flow | ¥0 | ¥15.00M | -¥3.37M |
| Dividends Paid | -- | -¥322K | -¥9.60M |
| Financing Cash Flow | ¥43.66M | -¥30.09M | ¥8.87M |
| Net Change in Cash | ¥37.23M | -¥459K | -¥576K |
Cash Flow Statement (Quarterly) · Reported in CNY · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|
| Gross Margin | 2.8% | 6.2% | 5.1% |
| Operating Margin | -43.1% | 0.0% | 0.7% |
| Net Profit Margin | -37.6% | -1.5% | -1.2% |
| Return on Equity (ROE) | -28.4% | -- | -- |
| Return on Assets (ROA) | -18.8% | -2.3% | -- |
| Current Ratio | 2.76x | 0.84x | -- |
| Quick Ratio | 2.74x | 0.84x | -- |
| Debt to Equity | 0.23x | -- | -- |
| Revenue Growth (YoY) | -61.0% | +6.1% | -- |
| Gross Profit Growth (YoY) | -82.5% | +27.8% | -- |
| Operating Income Growth (YoY) | -- | -100.3% | -- |
| Operating Cash Flow Growth (YoY) | -143.9% | -- | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.